 
 |
|
Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122
Date: February 25, 2010
Client: Regulus Therapeutics
Summary: Carlsbad, CA., February 25, 2010 – Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.
|
|
|
|
 |
|
febit Launches New Instrument for Targeted NextGen Sequencing With High Sample Throughput at AGBT Conference
Date: February 17, 2010
Client: febit
Summary: LEXINGTON, Mass. and HEIDELBERG, Germany, Feb. 17 /PRNewswire/ -- febit today announced the launch of its HybSelector, a new instrument for high throughput targeted resequencing, at the 11th annual Advances in Genome Biology and Technology (AGBT) meeting on February 24-27, 2010, in Marco Island, Florida. AGBT is now widely regarded as the premier scientific forum for sharing information about the latest advances in new DNA sequencing technologies and their application to diverse areas in biology and biomedical research. The new HybSelector instrument will replace the Geniom RT Analyzer for high-quality DNA enrichment followed by targeted next-generation sequencing. The compact HybSelector combines febit's well established expertise in the development and manufacture of technologies for genome exploration with the most advanced high-quality DNA enrichment automation available on the market.
|
|
|
|
 |
|
Otonomy Receives FDA Clearance to Initiate Clinical Trial in Patients with Meniere's Disease
Date: February 17, 2010
Client: Otonomy, Inc.
Summary: SAN DIEGO, Feb. 17 /PRNewswire/ -- Otonomy, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of OTO-104 in patients with Meniere's disease, a debilitating disorder of the inner ear affecting balance and hearing.
|
|
|
|
 |
|
Marcadia Initiates Phase 1 Clinical Trial of GLP-1/GIP Dual Agonist MAR701
Date: February 17, 2010
Client: Marcadia Biotech Inc.
Summary: INDIANAPOLIS, Feb. 17, 2010 – Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.
|
|
|
|
 |
|
Clinical Data Presented at JIM 2010 Provide Further Evidence that the Genous™ Bio-engineered R stent™ Could Be a Treatment of Choice for Patients Not Suitable for Long Term Dual Antiplatelet Therapy
Date: February 15, 2010
Client: OrbusNeichv
Summary: Rome, Feb. 15, 2010 – OrbusNeich announced that clinical data presented at the Joint Intervention Meeting (JIM) 2010 in Rome provide further evidence that the company’s Genous stent could be a treatment of choice for patients not suitable for long term dual antiplatelet therapy. The investigator initiated, 50 patient, multicenter study evaluated the safety of patients receiving only 10 days dual antiplatelet therapy undergoing stenting with the Genous Bio-engineered R stent. The primary endpoint was the absence of stent thrombosis or any occlusion within three months.
|
|
|
|
|
|
OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous™ Bio-engineered R stent™ in China
Date: February 11, 2010
Client: OrbusNeich
Summary: HONG KONG, Feb. 11, 2010 – OrbusNeich today announced that the first patient has been enrolled in a randomized clinical trial of the Genous Bio-engineered R stent in China.
|
|
|
|
 |
|
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025
Date: February 9, 2010
Client: Debiopharm Group
Summary: Lausanne, Switzerland - February 9, 2010 - Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.
|
|
|
|
 |
|
Cellular Dynamics launches human iPSC-derived cardiomyocytes
Date: February 8, 2010
Client: Cellular Dynamics International
Summary: MADISON, Wis.—Although it initiated the commercial launch of its iCell Cardiomyocytes in mid December, Cellular Dynamics International (CDI) says the story of its breakthrough launch is still very much a work in progress, as it rolls out the commercialization of the induced pluripotent stem cell-derived line in stages, with an expectation that the iCell Cardiomyocytes program will be fully up-and-running by the time of the 49th Annual Meeting and ToxExpo of the Society of Toxicology (SOT) that is being held March 7 to 11 at Salt Lake City’s Salt Palace Convention Center.
|
|
|
|
 |
|
Arena Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Date: February 4, 2010
Client: Arena Pharmaceuticals, Inc.
Summary: SAN DIEGO, Feb. 4, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time) at the Waldorf-Astoria Hotel in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company, including its clinical development and discovery programs.
|
|
|
|
 |
|
Pluristem's PLX Cells May Effectively Treat Ischemic Stroke - Brain Research Journal Reports
Date: February 3, 2010
Client: Pluristem Therapeutics Inc.
Summary: HAIFA, Israel--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that the results of a pre-clinical study in an animal model of ischemic stroke demonstrated that its PLacental eXpanded (PLX) cell therapy may be an effective treatment for this disorder. Results will be published in the journal Brain Research (Brain Research, Feb. 22, Vol. 1315) under the title “Transplantation of placenta-derived mesenchymal stromal cells upon experimental stroke in rats.” The study was conducted in collaboration with the Fraunhofer Institute for Immunology and Cell Therapy (IZI) in Leipzig, Germany.
|
|
|
|
 |
|
Savara Breathes Life into Inhaled Therapeutics
Date: February 1, 2010
Client: Savara Pharmaceuticals
Summary: Inhalable therapeutics offer a new formulation option and delivery route for existing drugs that are losing patent protection or need to become more efficient. Inhaled drugs should ideally be one to three microns in diameter, the best size for delivery into the deep lung for local and systemic absorption.
|
|
|
|
 |
|
New Form of Stem Cell Communication Rescues Diseased Neurons
Date: February 1, 2010
Client: Sanford-Burnham Medical Research Institute
Summary: LA JOLLA, Calif., February 1, 2010 -- Investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham, formerly Burnham Institute for Medical Research), the Karolinska Institutet, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School and Université Libre de Bruxelles have demonstrated in mouse models that transplanted stems cells, when in direct contact with diseased neurons, send signals through specialized channels that rescue the neurons from death. These direct cell-to-cell connections may also play a role in normal development by laying down the blueprint for more mature electrical connections between neurons and other cells. The research was published in the journal Proceedings of the National Academy of Sciences on February 1.
|
|
|
|
|
